Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
about
Sequence of treatment in locally advanced and metastatic renal cell carcinomaImaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyClinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma PatientsRecent updates in renal cell carcinomaSafety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinTargeted therapies in renal cell cancer: recent developments in imagingValidation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Sunitinib and other targeted therapies for renal cell carcinoma.Clinical utility of quantitative imaging.RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.MRI phenotype in renal cancer: is it clinically relevant?The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyImaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Vascularity of primary and metastatic renal cell carcinoma specimens.Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.Imaging of renal cell carcinoma: state of the art and recent advances.Imaging assessment of tumor response: past, present and future.Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.Metastatic renal cell cancer.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Systematic review of minimally invasive ablation treatment for locally advanced pancreatic cancer.Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy.Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.
P2860
Q26773653-FD26DC2A-F79F-4048-BEB2-B3E56064128AQ26863654-9241752B-62A6-4452-804C-C12537DE1EEBQ33577856-0189F932-6016-4924-8D28-49D8086FBB20Q33633431-2BBA6953-3F1A-4092-8EF2-F83786DF3842Q33652589-1B7CBEC9-B715-427C-BD6C-CE8E36786B8FQ33745827-3741A0C0-D024-41D1-A5BE-BBEE79058513Q33770680-D3682A77-FD26-4E32-894D-060C9C567675Q33869697-4BDA7EA2-0E0A-4BC0-8E8D-9CC8CDB6E460Q34003369-404F156C-F183-4352-A756-2C82AD71EB86Q34018372-CFFB4EAF-9756-4DAA-B9ED-AF3C595B7961Q34088696-102D3FFF-BB35-4BB4-9E62-5DBFF0F020DAQ34465123-FD7C2DD4-E2EE-433A-B292-57E7E80D67B8Q34537285-E9F81346-62F1-462F-A9D7-4DE134C939D4Q34621802-A9A27991-F24F-4F7B-A918-36CCE00C4034Q34656915-D919AFBF-4BFD-46F4-99FE-4BEDBF01CF68Q35156636-F820C280-26FE-436A-BD56-1C67CBF4714AQ35230406-E3DB5E15-790D-43A2-846B-532842DF062FQ35793032-025F5E87-8E27-44B4-8697-DE32E52E48BFQ35918881-8E28FBF0-D68D-45AE-A151-C286F991CE4EQ36567385-C00D7552-684F-47C0-8CFB-42961FF843C7Q36578610-3D3A7CDD-FF78-4A47-8A10-CAACCF984E9AQ36907986-5CE58DA7-1319-4CD8-9BFE-6BC78D9535EBQ37185773-5DC9CCD5-857D-4D99-AC9D-47E7199DCF5BQ37385255-F5FE1ED4-BA6A-46E0-BB01-7C7DF6686EDDQ37589551-E5B5135A-CF8D-44B6-AEDD-71237690B462Q37602345-A1E38FED-76F4-403E-A2B4-9079814EAC38Q37729968-BC909396-7ECE-4338-8CB8-8C41563FAB67Q37819763-746371B4-2E34-45C7-8150-9AC71FF675DFQ37875082-3356A6FC-5F80-4703-B04D-D2D2612FD69EQ38012779-40CDB1A4-264D-48F9-90A2-CFEF4A2C78B4Q38141650-CE2B1AD9-DADB-416F-8A0E-2734A03269D0Q38171327-0C09252B-691B-436D-B847-D1B879A5036AQ38171376-2398978E-43BD-4524-B7E3-AC76207A8E78Q38196855-C9EC81C8-8BE2-443D-8FB5-F6AD822FFBADQ38224996-8A341805-DF44-41CD-A223-E36A610119B1Q38837758-49E3191F-14A8-4E50-A860-14BC44659107Q40707153-990FCF3E-B568-45ED-8B23-7556A0E7B312Q41042295-71EE9617-F8EE-4381-A523-C429C663B2E4Q41162248-D01B0D3F-54D6-4867-A3BA-16AA05300672Q41754200-9DD9DB78-BD3A-4452-90CF-4A70DA519937
P2860
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Choi response criteria for ear ...... cancer treated with sunitinib.
@ast
Choi response criteria for ear ...... cancer treated with sunitinib.
@en
type
label
Choi response criteria for ear ...... cancer treated with sunitinib.
@ast
Choi response criteria for ear ...... cancer treated with sunitinib.
@en
prefLabel
Choi response criteria for ear ...... cancer treated with sunitinib.
@ast
Choi response criteria for ear ...... cancer treated with sunitinib.
@en
P2093
P2860
P356
P1476
Choi response criteria for ear ...... cancer treated with sunitinib.
@en
P2093
A A M van der Veldt
A J M van den Eertwegh
J B A G Haanen
M R Meijerink
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605567
P407
P577
2010-02-09T00:00:00Z
P5875
P6179
1000486855